8/104 sources · 2 publishersUpdated Oct 8, 15:05 UTC
Sagimet raises $115 million after positive long-term acne drug data
Sagimet Biosciences announced a $115 million equity financing at $10 per share to support a U.S. Phase 3 study of its acne treatment denifanstat. In a China extension study lasting up to 52 weeks, denifanstat achieved a 57% treatment-success rate, while total lesions and inflammatory lesions declined 72% and 77%, respectively. The company plans to begin patient screening for the U.S. study in October.
Why it matters
The financing is intended to pay for the U.S. Phase 3 program and related launch preparation. Sagimet says its June 30 liquidity should support operations through 2028, giving it funding to execute the planned trial.
Key facts
- 1Sagimet announced a $115 million financing priced at $10 per share, together with pre-funded warrants. newsable.asianetnews.com
- 2In the China extension trial, denifanstat produced a 57% treatment-success rate after up to 52 weeks. newsable.asianetnews.com
- 3Total acne lesions decreased 72% and inflammatory lesions decreased 77% in the China study. newsable.asianetnews.com
- 4Sagimet expects the U.S. Phase 3 trial to recruit about 800 patients aged 12 and older, including roughly 450 adolescents. newsable.asianetnews.com
- 5The company held $257.6 million in cash, cash equivalents and marketable securities on June 30 and said this funding should last through 2028. newsable.asianetnews.com
Open questions
- Materials reported different premarket share-price gains: 13% in material 1 and 12% in material 2.
Summary written by AlphAI from 3 of 4 sources. Not investment advice. Figures are as stated by the linked sources.